Official HCP site for YUVIWEL® (navepegritide)

The first and only FDA-approved, once-weekly treatment for use in children with achondroplasia¹

is now approved

YUVIWEL is indicated to increase linear growth in children 2 years of age and older with achondroplasia with open epiphyses.¹

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Prescribing Information

See important information about YUVIWEL.

Download now

Want to stay in touch for updates?

Connect with us

Interested in learning more about YUVIWEL for your patients with achondroplasia?
Please fill out the form below for updates and resources.

*Required field.

I would like an Ascendis representative to contact me

First Name*

Last Name*

Email Address*

Zip Code*

Specialty*

NPI Number

Privacy Notice

By checking this box, I certify that I am a resident of the United States and 18 years or older and agree to Ascendis Pharma Terms of Use. I understand and agree that the information I provide will be used in line with the Ascendis Pharma Privacy Policy, including to provide me with marketing information, such as newsletters and updates, and to contact me for my opinion regarding products, programs, and services.

I understand that at any time I may unsubscribe by clicking on the designated link in the material.

Click here to agree*

Consent

By checking this box, I confirm that I have given my consent to the collection and processing of the information provided as answers marked with *. This information will solely be used to tailor our communications to you. You may at any time withdraw your consent. For more information, please see our Privacy Policy.

Click here to agree*

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INDICATION AND USAGE

YUVIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.

This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

INDICATION AND USAGE

YUVIWEL is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Risk of Low Blood Pressure

Transient decreases in blood pressure have been reported with a once-daily C-type natriuretic peptide (CNP) analog. Subjects with hemodynamically significant cardiovascular disease were excluded from participation in YUVIWEL clinical trials. Advise patients to contact their healthcare provider if they experience symptoms of decreased blood pressure (eg, dizziness, fatigue, and/or nausea) while being treated with YUVIWEL.

ADVERSE REACTIONS

The most common adverse reactions (≥5%) are vomiting, injection site reaction, pain in extremity, and nausea.

SPECIFIC POPULATIONS

Pregnancy and Lactation

There are no available data on the use of YUVIWEL in pregnant women, or data on the presence of YUVIWEL in human milk, the potential effects on milk production or the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for YUVIWEL and any potential adverse effects on the breastfed infant from YUVIWEL or from the underlying maternal condition.

Renal Impairment

YUVIWEL is not recommended for patients with moderate or severe renal impairment.

You are encouraged to report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.

Reference: 1. Yuviwel. Prescribing information. Ascendis Pharma, Inc.; 2026.